BNET Industries
Market Cap:$2.4B
Last Fiscal Year Sales:$1.5B
- Public
- US
Dow Jones Description
PPD supports the drug industry in improving health. Founded in 1985 and headquartered in Wilmington, NC, Pharmaceutical Product Development, Inc. (NASDAQ: PPDI) provides services to the pharmaceutical industry. The company operates in two segments: Discovery Sciences and Development. It offers discovery and development services, laboratory services, data management, regulatory consulting, test subject recruiting, and more. Customers include pharmaceutical, biotechnology, and medical firms and government organizations. It operates in North America, South America, and Europe. The company has annual revenue of about $1 billion and employs more than 10,400 people. In 2005, Standard & Poor's named PPD to its MidCap 400, reflecting the market's recognition of it's growth and value. In February 2005, the company acquired substantially all of the assets of SurroMed, Inc.'s biomarker business.
Number of Employees 10,500
Contact Information
929 North Front Street
Wilmington, North Carolina 28401-3331
(910) 251-0081
Peer Companies
NAICS Code Research and Development in the Physical, Engineering, and Life Sciences: 54171
Recent Events
-
Pharmaceutical Product Development PPDI Dow
-
Pharmaceutical Product Development PPDI Downgraded By Wells Fargo
-
PPD buys CRO, creates spin-offs and invests $100M in Celtic
-
BRIEF-PPD to invest $100 mln in Celtic Therapeutics Holdings
-
PPD Announces Plans to Spin off Compound Partnering Business
-
PPD makes major moves; shares slide
-
Pharmaceutical Product Development PPDI Reports Inline Q3 EPS of $0.32
-
PPD expands presence in China with acquisition
-
BRIEF-RESEARCH ALERT-Jefferies raises targets on PPD, 2 others
-
Ahead of the Bell: Pharma Product Development Inc.
-
PPD Opens Global Central Lab in Singapore
-
PPD names Covington head of observational studies
-
Dow's hot streak still alive; S&P, Nasdaq succumb into red
-
Pharma Product Development PPDI Downgraded By Barclays Capital
-
PPDI shares fall after analyst downgrades
-
PPD Declares Third Quarter Dividend
-
Pharmaceutical Product Development shares plunge 10%
-
PPD Q2 Earnings At $0.49 Including Gain On Piedmont Research Center Sale - Update
News & Analysis
Filter by
pharmaceutical product development inc. - All News and Analysis
PPD Makes Significant Inroad into China Biotech with Single Deal
Seeking Alpha
- 2009-10-28
ChinaBio Today submits: PPD, Inc. (NSDQ: PPDI) announced it has reached an agreement to acquire Excel PharmaStudies, Inc., a China-based CRO specializing in Phase II-IV clinical trials. Founded in 2000, Excel has offices in 15 China cities and over 300 employees. It has worked with more than 120 pharmas...
Pharmaceutical Product Development, Inc., Q4 2008 Earnings Call Transcript
Seeking Alpha
- 2009-02-10
Question-and-Answer SessionOperator Operator Instructions. Your first question comes from the line of Randall Stanicky of Goldman Sachs & Company. Your line is open. Randall Stanicky - Goldman Sachs Great. Thanks very much for the questions, guys. I just have two, first on the cost reductions which were pretty...
Pharmaceutical Product Development, Inc., 2009 Guidance Call Transcript
Seeking Alpha
- 2009-01-15
Earnings Call ExcerptPharmaceutical Product Development, Inc. PPDI 2009 Guidance Call January 15, 2009 9:00 am ET Executives Dr. Fredric N. Eshelman - Vice Chairman and Chief Executive Officer Daniel G. Darazsdi - Chief Financial Officer William J. Sharbaugh - Chief Operating Officer Analysts John Kreger - William...
Pharmaceutical Product Development, Inc. Q3 2008 Earnings Call Transcript
Seeking Alpha
- 2008-10-22
Question-and-Answer SessionOperator Operator Instructions. Your first question comes from the line of Randall Stanicky with Goldman Sachs. Your line is open. Randall Stanicky - Goldman Sachs Great. Thanks a lot. Fred, just as a first question on cancellations, can you just maybe walk us through? If we look at...
Analyst Reports for Pharmaceutical Product Development Inc., Inergy L.P, Freeport-McMoRan Copper & Gold Inc. and Motorola Inc.
- 2008-10-13
MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Through our numerous partnerships with many of the top investment minds in the world, we provide research on companies making a move in the markets. Investors seeking genuine analyst opinions on their investments for Pharmaceutical...
CROs: The 'Big Pharma Effect'
Seeking Alpha
- 2008-08-28
Ryan Savitz submits: I have not been the first nor will I be the last to point out the troubles of Big Pharma; however, how can you as an investor take advantage of the weak sub-sector and transfer your investments to another attractive area of Healthcare that will be reaping...
When To 'Believe the Hype' of a New Product
Seeking Alpha
- 2008-08-25
Larry Bellehumeur submits: When it comes to "Hyping" a product, it is clear to most people that Apple AAPL has no peers. Long before people knew the total functionality of an iPod, they knew that they had to have one. In my opinion, this was the most successful product...
Hedge Fund Tracking: Tremblant Capital
Seeking Alpha
- 2008-08-14
Market Folly submits: Four times a year, hedge funds & asset managers with > $100 million AUM assets under management are required to report to the SEC their holdings from the previous quarter. I check these 13F filings quarterly just to get a sense as to where these funds are...
Pharmaceutical Product Development Inc. Q2 2008 Earnings Call Transcript
Seeking Alpha
- 2008-07-23
Question-and-Answer Session Operator Thank you. Operator Instructions. We'll pause for just a moment to compile the Q&A roster. Your first question comes from the line of Randall Stanicky of Goldman Sachs. Randall Stanicky - Goldman Sachs Thanks very much for the question Fredric. Can you just help us...
Pharmaceutical Product Development Inc. Q1 2008 Earnings Call Transcript
Seeking Alpha
- 2008-04-23
Question-and-Answer SessionOperator Operator Instructions. Your first question will be from the line of Randall Stanicky with Goldman Sachs% Randall Stanicky - Goldman Sachs. Thanks very much for the questions. Fred, just a quick clarification, given the working site, is there any change to guidance, just wondering? Fred Eshelman No....
- 1
- 2
Industry Transcripts by Seeking Alpha
-
Dialysis Corporation of America Q3 2009 Earnings Call Transcript
on Nov 07, 2009about DCAI
-
Medical Action Industries Inc. Q2 2010 Earnings Call Transcript
on Nov 06, 2009about MDCI
-
Millipore Corporation Q3 2009 Earnings Call Transcript
on Nov 05, 2009about MIL
-
Coherent Inc. F4Q09 (Qtr End 10/03/2009) Earnings Call Transcript
on Nov 05, 2009about COHR
-
ResMed Inc. Q1 2010 Earnings Call Transcript
on Nov 05, 2009about RMD
Glass Door
Pharmaceutical Product Development
IndustryTop Rated
- Why So Many Insured People Have Big Medical Debts 5 votes
- Physicians Know We Need Reform 4 votes
- Hospital Chain's Turnaround Raises Health Spending 3 votes
- Healthcare Is Still Adding Jobs, Despite Recession 3 votes
- Healthcare Roundup: Medical Office Space in Demand, Blues Companies See Lower Income, Two Sides of Health Insurance, and More 3 votes
